在根据肿瘤雌激素和孕激素受体水平分层接受内分泌治疗的女性中，肿瘤孕激素受体水平较高的患者比肿瘤孕激素受体水平较低的患者预后更好。

Amongst Women Stratified to Receive Endocrine Therapy on the Basis of Their Tumor Estrogen and Progesterone Receptor Levels, Those with Higher Tumor Progesterone Receptor Levels Had a Better Outcome Than Those with Lower Levels of Tumor Progesterone Receptor.

作者信息

Lin Tai-Han, Gao Hong-Wei, Liao Guo-Shiou, Yu Jyh-Cherng, Dai Ming-Shen, Ho Jar-Yi, Yu Cheng-Ping

机构信息

Department of Pathology and Graduate Institute of Pathology and Parasitology, Tri-Service General Hospital, National Defense Medical Center, No. 161, Section 6, Minquan E. Road, Neihu District, Taipei 114, Taiwan.

Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan.

出版信息

Cancers (Basel). 2021 Feb 21;13(4):905. doi: 10.3390/cancers13040905.

BACKGROUND

To realize the association between stratified expression levels of ER and PgR and long-term prognosis of breast cancer patients who received adjuvant hormone therapy, this study aimed to propose better prognostic cut-off levels for estrogen receptor (ER) and progesterone receptor (PgR).

METHODS

Patients who received adjuvant hormone therapy after surgical intervention were selected. The ER and PgR status and their effects on breast cancer-specific survival (BCSS) and disease-free survival (DFS) over 5 and 10 years were evaluated. Next, subgroups were generated based on ER and PgR expression percentage and Allred scores. Survival curves were constructed using the Kaplan-Meier method.

RESULTS

ER and PgR expression were significantly associated with better prognosis in 5 years, whereas only PgR expression was significantly associated during the 10-year follow-up. The optimal cut-off values for better 5-year BCSS were ER > 50%; ER Allred score > 7; PgR ≥ 1%; or PgR Allred score ≥ 3; the corresponding values for DFS were ER > 40%; ER Allred score > 6; PgR > 10%; or PgR Allred score ≥ 3. In the long-term follow-up, PgR of > 50% or Allred score of > 5 carriers revealed a better prognosis of both BCSS and DFS.

CONCLUSION

Patients with a PgR expression > 50% or an Allred score > 5 exhibited better 10-year BCSS and DFS.

背景

为了解雌激素受体（ER）和孕激素受体（PgR）的分层表达水平与接受辅助激素治疗的乳腺癌患者长期预后之间的关联，本研究旨在提出雌激素受体（ER）和孕激素受体（PgR）更好的预后临界值。

方法

选取接受手术干预后进行辅助激素治疗的患者。评估ER和PgR状态及其对5年和10年乳腺癌特异性生存（BCSS）和无病生存（DFS）的影响。接下来，根据ER和PgR表达百分比及艾尔雷德评分生成亚组。采用Kaplan-Meier法构建生存曲线。

结果

ER和PgR表达在5年时与更好的预后显著相关，而在10年随访期间只有PgR表达与预后显著相关。5年更好的BCSS的最佳临界值为ER>50%；ER艾尔雷德评分>7；PgR≥1%；或PgR艾尔雷德评分≥3；DFS的相应临界值为ER>40%；ER艾尔雷德评分>6；PgR>10%；或PgR艾尔雷德评分≥3。在长期随访中，PgR>50%或艾尔雷德评分>5的携带者在BCSS和DFS方面均显示出更好的预后。